OOIR: Observatory of International Research

Papers

(The median citation count of Melanoma Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study	50
Rurality as a predictor of melanoma stage and treatment in Indiana: a retrospective cohort study	36
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	26
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	25
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	23
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	19
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	19
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases	18
CTLA-4 and TNFRSF1B genetic variants in clinicopathological aspects and outcome of cutaneous melanoma	18
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	18
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	16
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	15
Chromosome 1p13.2 gene cluster upregulation in neuroblastoma RAS viral oncogene homolog pathogenic variant melanoma: a potential biomarker axis	14
Brain metastases during follow-up of patients with resected cutaneous melanoma	13
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	13
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study	13
Real-world recurrence-free and distant metastasis-free survival in early-stage melanoma: concordance with KEYNOTE-716 trial estimates	13
Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors	12
Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study	12
Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis	11
Immunotherapy-induced granulomatous reaction in patients with melanoma	10
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	10
Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors	10
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	9
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum	8

Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma	8
Ultraviolet A radiation exposure and melanoma: a review	8
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy	8
Divergent pathways of melanoma development: evidence from a Southern European cohort	8
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma	8
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma	8
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	8
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients	7
Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors	7
Multiple melanoma, ichthyosis, and juvenile cataracts in a patient with a germline mutation in CDKN2A: pure coincidence or related association?	7
Safety of tranexamic acid in patients with stage III melanoma undergoing lymph node dissection: a retrospective cohort study	6
Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporti	6
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight	6
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study	6
Novel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines	6
Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study	6
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	6
Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis	6
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	6
Immune-related cholecystitis following combination therapy with nivolumab and ipilimumab in a patient with metastatic melanoma: a case report and literature review	5
Expression and prognostic value of cyclase-associated proteins in cutaneous melanoma	5
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins	5
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity	5
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis	5
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	5
Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to	5
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	5
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	5
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma	4
Tebentafusp-associated dermatological adverse events in patients with metastatic uveal melanoma: a single-center retrospective cohort study	4
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	4
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	4
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	4
Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials	4
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	4
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	4
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	4
Melanoma risk during immunomodulating treatment	4
Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update	4
Survival and toxicity profile of elderly melanoma patients treated with immune checkpoint inhibitors: a retrospective study from a tertiary care center	4
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	4
Simultaneous melanomas in the setting of multiple primary melanomas	4
Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observation	4
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	4
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	4
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies	4
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition	4
Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma	4
Melanoma and pregnant women: a systematic review and meta-analysis	3
Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature	3

First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma	3
High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma	3
ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells	3
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA)	3
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)	3
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition	3
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma	3
A deep learning-based radiomics model for noninvasive diagnosis of melanoma	3
The London Melanonychia Assessment Tool for the identification of malignant lesions in patients presenting with melanonychia	3
Immune checkpoint inhibitor-associated uveitis in metastatic melanoma: case report and literature review	3
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	3
Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma	3
Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas	3
Psychosocial wellbeing in people with melanoma in-situ: a systematic review	3
FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanoma	3
Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients?	3
Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis	3
Upregulation of SFTPC gene expression is associated with disease progression and worse survival outcomes in human skin melanomas	3
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis	3
Molecular profiling of primary uveal melanoma: results of a Polish cohort	3
Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy	3
Breaking barriers: epithelial–mesenchymal transition role in melanoma invasion and resistance	3
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy	3
Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis	3
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies	3
Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice	3
Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models	3
A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site	3
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma	2
Retro- and prospective histologic and immunohistochemical analysis of safety margins following complete excision of less than 1 mm melanomas	2
Development and validation of prognostic nomogram in pediatric melanoma: a population-based study	2
Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy	2
Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals	2
The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective	2
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	2
Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma	2
Talimogene laherparepvec monotherapy for head and neck melanoma patients	2
Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy	2
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma	2
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma	2
The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic	2
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series	2
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma	2
Epidemiologic characteristics of de novo versus nevus-associated melanoma	2
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study	2
The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio	2
New technique for in-continuity axillary and supraclavicular lymphadenectomy for advanced metastatic melanoma using intraoperative image guidance: a case report	2
Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia	2
Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients	2
Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients	2
Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies	2
Prognostic significance of tumor budding in melanoma	2
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis	2
Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results	2
Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients	2
The effect of COVID-19 on early melanoma detection	2
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization	2
Dermatologic surveillance in healthy carriers of CDKN2A and p.E318K MITF germline variants from melanoma-prone families: a 14 years hospital-based experience	2
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab	2
The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis	2
Melanoma risk prediction based on a polygenic risk score and clinical risk factors	2
Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients	2
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma	2
Expect the unexpected: a saying to bear in mind	2
Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene	2
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective	2
pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma	2
Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study	2
Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020	2
Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case	2
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma	2
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma	2
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome	2